News

Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, ...
US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials ...
In this paper, a comprehensive pharmacokinetic model for different insulin formulations including insulin Glargine is developed based on the model proposed by Trajanoski et al. (1993). Current models ...
IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.
An experimental once-weekly insulin known as efsitora has shown comparable effectiveness to daily insulin regimens in managing blood sugar levels among adults with type 2 diabetes, according to ...
Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...
Biocon Biologics Ltd. (BBL) on Monday announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the supply of ...
Insulin efsitora alfa (efsitora), a once-weekly basal insulin, has the potential to reduce the treatment burden of people with type 2 diabetes who require insulin. We aimed to assess the efficacy and ...
FRIDAY, June 27, 2025 (HealthDay News) -- Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among ...
Insulin Pump Risks and Benefits A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs. A Joint Statement of the European Association for the Study of Diabetes ...
compared with once-daily insulin glargine U100 (8.28% to 7.08%) over 52 weeks in insulin-naïve adults with type 2 diabetes (the estimated between-group difference of -0.03 percentage points, 95% CI -0 ...